Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Adenosine receptors: new opportunities for future drugs.
- S. Poulsen, R. Quinn
- Biology, Medicine
- Bioorganic & medicinal chemistry
- 1 June 1998
This review summarises current knowledge on adenosine receptors, an important G protein-coupled receptor. The four known adenosine receptor subtypes A1, A2A, A2B, and A3 are discussed with special… Expand
Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery
- Sandra Duffy, M. Sykes, +6 authors V. Avery
- Biology, Medicine
- Antimicrobial Agents and Chemotherapy
- 3 July 2017
ABSTRACT Open-access drug discovery provides a substantial resource for diseases primarily affecting the poor and disadvantaged. The open-access Pathogen Box collection is comprised of compounds with… Expand
Therapeutic applications of glycosidic carbonic anhydrase inhibitors
- Jean-Yves Winum, S. Poulsen, C. Supuran
- Chemistry, Medicine
- Medicinal research reviews
- 1 May 2009
The zinc enzymes carbonic anhydrases (CAs, EC 4.2.1.1) are very efficient catalysts for the reversible hydration of carbon dioxide to bicarbonate and hence play an important physiological role. In… Expand
Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum--the η-carbonic anhydrases.
- S. Del Prete, D. Vullo, +4 authors C. Supuran
- Chemistry, Medicine
- Bioorganic & medicinal chemistry letters
- 15 September 2014
The genome of the protozoan parasite Plasmodium falciparum, the causative agent of the most lethal type of human malaria, contains a single gene annotated as encoding a carbonic anhydrase (CAs, EC… Expand
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
- Brendan L Wilkinson, L. Bornaghi, T. Houston, A. Innocenti, C. Supuran, S. Poulsen
- Chemistry, Medicine
- Journal of medicinal chemistry
- 27 September 2006
Aryl and heteroaryl sulfonamides (ArSO(2)NH(2)) are therapeutically used to inhibit the catalytic activity of carbonic anhydrases (CAs). Using a "click-tail" approach a novel class of glycoconjugate… Expand
Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
- Brendan L Wilkinson, L. Bornaghi, +4 authors S. Poulsen
- Chemistry, Medicine
- Journal of medicinal chemistry
- 8 March 2007
We report the synthesis of a series of benzene sulfonamides containing triazole-O-glycoside tails for evaluation as carbonic anhydrase (CA) inhibitors. These glycoconjugates were synthesized by the… Expand
Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors.
- J. C. Morris, J. Chiche, +6 authors S. Poulsen
- Chemistry, Medicine
- Journal of medicinal chemistry
- 2 September 2011
Carbonic anhydrase (CA) enzymes, specifically membrane-bound isozymes CA IX and CA XII, underpin a pH-regulating system that enables hypoxic tumor cell survival and proliferation. CA IX and XII are… Expand
Structural Insights into Carbonic Anhydrase IX Isoform Specificity of Carbohydrate-Based Sulfamates
- Janina Moeker, B. Mahon, +4 authors S. Poulsen
- Chemistry, Medicine
- Journal of medicinal chemistry
- 25 September 2014
Carbonic anhydrase IX (CA IX) is an extracellular transmembrane homodimeric zinc metalloenzyme that has been validated as a prognostic marker and therapeutic target for several types of aggressive… Expand
Inhibition of carbonic anhydrase isozymes with benzene sulfonamides incorporating thio, sulfinyl and sulfonyl glycoside moieties.
- M. Singer, M. Lopez, +4 authors S. Poulsen
- Chemistry, Medicine
- Bioorganic & medicinal chemistry letters
- 15 April 2009
A series of benzene sulfonamides incorporating thio, sulfinyl or sulfonyl glycoside moieties were synthesized. These glycoconjugates were investigated for their ability to inhibit the enzymatic… Expand
Anti-mycobacterial activity of a bis-sulfonamide.
- Brendan L Wilkinson, L. Bornaghi, A. Wright, T. Houston, S. Poulsen
- Chemistry, Medicine
- Bioorganic & medicinal chemistry letters
- 1 March 2007
A bis-arylsulfonamide, 7, has been identified that exhibits growth inhibition of Mycobacterium smegmatis at less than 25 microg/mL, but has no such activity against Escherichia coli or Staphylococcus… Expand